**Supplemental Table 1. Use of Thrombolytics**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristic** | **Thrombolytic Use (n=177)** | **No Thrombolytic Use (n=88)** | **P value** |
| *Comfort level* |
| Cardiac arrest secondary to known pulmonary embolism Not at all comfortable Somewhat uncomfortable Somewhat comfortable Very comfortable | 1 (0.6)2 (1.1)26 (14.8)147 (83.5) | 7 (8)9 (10.2)24 (27.3)48 (54.6) | <0.01 |
| Cardiac arrest secondary to suspected thromboembolic event Not at all comfortable Somewhat uncomfortable Somewhat comfortable Very comfortable | 2 (1.1)19 (10.8)87 (49.4)68 (38.6) | 12 (13.6)23 (26.1)39 (44.3)14 (15.9) | <0.01 |
| Massive pulmonary embolism Not at all comfortable Somewhat uncomfortable Somewhat comfortable Very comfortable | 2 (1.1)4 (2.3)26 (14.9)143 (81.7) | 4 (4.6)4 (4.6)23 (26.1)57 (64.8) | 0.01 |
| *Local Practices* |
| Policy or guideline pertaining to thrombolytic use in cardiac arrest, n (%) | 49 (27.8) | 12 (13.6) | <0.01 |
| Pulmonary Embolism Response Team, n (%) Team in place Team being developed | 43 (24.4)25 (14.2) | 14 (15.9)3 (3.4) | <0.01 |
| Formulary thrombolytic, n (%) Alteplase Streptokinase Tenecteplase Reteplase | 174 (98.3)13 (7.3)49 (27.7)11 (6.2) | 85 (96.6)11 (12.5)10 (11.4)8 (9.1) | 0.380.17<0.010.39 |
| Locations for thrombolytic storage\*, n (%) Emergency department automated dispensing cabinet Intensive care unit automated dispensing cabinet Central pharmacy  Pharmacy satellite Unknown  | 74 (41.8)50 (28.3)149 (84.2)39 (22)13 (7.3) | 24 (27.3)12 (13.6)64 (72.7)12 (13.6)23 (26.1) | 0.02<0.010.030.14<0.01 |
| Thrombolytic preparation location, n (%) At the bedside by a nurse only  At the bedside by a pharmacist only  At the bedside by either a nurse or a pharmacist In the central pharmacy In a pharmacy satellite | 22 (12.4)19 (10.7)50 (28.3)73 (41.2)9 (5.1) | 12 (14.3)7 (8.3)15 (17.9)37 (44.1)6 (7.1) | 0.18 |
| Thrombolytic dosing, n (%) Alteplase 100 mg IV over 2 hours  Alteplase ≥50 kg: 50 mg; <50 kg, 0.5 mg/kg; 10 mg IV bolus over 1 minute then remaining dose over 2 hours Alteplase 10 mg IV bolus over 1 minute then 90 mg over 2 hours Alteplase 50 mg IV bolus over 2 minutes; may repeat in 10-30 minutes if no return of spontaneous circulation Tenecteplase dose 30 to 50 mg IV bolus, depending on weight category Alteplase 100 mg IVP over 2 minutes Other | 17 (9.8)15 (8.6)15 (8.6)65 (37.4)40 (23)12 (6.9)10 (5.7) | 12 (14.8)5 (6.2)8 (9.9)18 (22.2)11 (13.6)2 (2.5)25 (30.9) | <0.01 |
| Anticoagulation initiation, n (%) Before and following thrombolytic therapy Concomitantly (<5 minutes) Immediately (5 minutes – 1 hour) after thrombolytic therapy 1 to <6 hours after thrombolytic therapy ≥6 to 24 hours after thrombolytic therapy After aPTT or anti-Xa level results are within or below target range (regardless of time since thrombolytic dose) | 35 (19.8)6 (3.4)29 (16.4)31 (17.5)22 (12.4)36 (20.3) | 14 (16.1)3 (3.5)17 (19.5)10 (11.5)18 (20.7)14 (16.1) | 0.58 |
| *Barrier to Using Thrombolytics, n (%)* |
| I have no barriers | 90 (50.9) | 35 (39.8) | 0.09 |
| Lack of comfort | 15 (8.5) | 13 (14.8) | 0.12 |
| Inadequate staff education | 19 (10.7) | 12 (13.6) | 0.49 |
| High cost of therapy | 11 (6.2) | 6 (6.8) | 0.85 |
| Formulary restrictions | 1 (0.6) | 2 (2.3) | 0.22 |
| Lack of evidence supporting use | 25 (14.1) | 24 (27.3) | 0.01 |
| Adverse outcomes outweigh benefit | 21 (11.9) | 20 (22.7) | 0.03 |
| Unknown patient history | 53 (29.9) | 28 (31.8) | 0.76 |

\*May add up to >100% as multiple responses were permitted